Procedures & Treatments

Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.

[powerpress]

Here is a brief and basic summary of the concept of why we're concerned not only about the cancer we can see but the potential cancer we can't.

Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

[powerpress]

Why do we care about lymph nodes when staging lung cancer?

Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.

[powerpress]

One of the challenges of the increased frequency of chest CT scans being done for screening of people at higher risk of lung cancer, or done more commonly for chest symptoms, is that lung nodules are very commonly found, but most the time they aren't cancer.  Most studies show that >90% of lung nodules are benign, but the majority lead to additional work-up, and in nearly 100% of cases, they cause anxiety for the patient. What if a blood test could help clarify the probability that someone doesn't have a lung cancer?

This Thursday, November 7th at 8 PM Eastern, 5 PM Pacific, we'll gather in the Twitterverse for another one hour #LCSM (lung cancer social media) tweet chat.

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of predictive biomarkers ERCC1 and RRM1 in advanced NSCLC.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.

[powerpress]